NCI Project Targets Cancer Awareness in Asian-American Community

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 12 No 1
Volume 12
Issue 1

BETHESDA, Maryland-The National Cancer Institute (NCI) has launched a 5-year, $7.6 million project at seven leading cancer centers to address the disease among Asian Americans. Although Asian Americans have a relatively low overall risk, their cancer incidence is rising faster than that of any other racial or ethnic group in the United States.

BETHESDA, Maryland—The National Cancer Institute (NCI) has launched a 5-year, $7.6 million project at seven leading cancer centers to address the disease among Asian Americans. Although Asian Americans have a relatively low overall risk, their cancer incidence is rising faster than that of any other racial or ethnic group in the United States.

Asian Americans also suffer disproportionately from several forms of the disease, including liver, stomach, and cervical cancer.

The Asian-American community consists of more than 30 distinct ethnic groups and includes about 800 languages and dialects. The Asian-American Network for Cancer Awareness, Research, and Treatment (AANCART) will develop cancer awareness and prevention programs for specific subpopulations. It also aims to increase the number of Asian Americans participating in cancer clinical trials, train more Asian-American health care workers in community cancer prevention, and do research to reduce the cancer burden of this segment of the US population.

The University of California, Davis, Cancer Center will serve as headquarters for the project. Moon S. Chen, Jr., PhD, of UC-Davis, will be the principal investigator.

Other centers participating in the program are the Dana-Farber Cancer Institute, Boston; Herbert Irving Comprehensive Cancer Center, Columbia University, New York; Solove Cancer Research Center, Ohio State University, Columbus; Fred Hutchinson Cancer Research Center, Seattle; University of California, San Francisco, Comprehensive Cancer Center; and the UCLA Jonsson Comprehensive Cancer Center, Los Angeles. 

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content